The Spectranetics Corporation announced that its Stellarex™ 0.014” Drug-coated Angioplasty Balloon (DCB) has received the CE mark. The Stellarex 0.014” device is designed to treat small vessels, below-the-knee disease, and challenging critical limb ischemia (CLI) in patients. The combination of the currently available Stellarex 0.035” and the new 0.014” line available in Europe expands Spectranetics’ comprehensive portfolio of next generation DCBs to treat complex disease states across the lower extremities.
Ascensia Diabetes Care announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the CONTOUR®NEXT ONE Blood Glucose Monitoring System (BGMS), marking a key step in making the next-generation system available to people living with diabetes in the U.S.
The device, created by scientists at Imperial College London and DNA Electronics, uses a drop of blood to detect HIV, and then creates an electrical signal that can be read by a computer, laptop or handheld device.
The disposable test could be used for HIV patients to monitor their own treatment.
Furthermore, the technology could enable patients with HIV to be managed more effectively in remote locations.
Scientists report that a specialized drug screen test using lab-grown human cells has revealed two classes of compounds already in the pharmaceutical arsenal that may work against mosquito-borne Zika virus infections.
In a summary of their work, published in Nature Medicine on Aug. 29, the investigators say they screened 6,000 existing compounds currently in late-stage clinical trials or already approved for human use for other conditions, and identified several compounds that showed the ability to hinder or halt the progress of the Zika virus in lab-grown human neural cells.
Beyond Verbal announced the results of a new study on Coronary Artery Disease (CAD) patients, conducted together with the Mayo Clinic. The research shows that voice analysis can be used to identify the presence of CAD by establishing a strong correlation between certain voice characteristics and CAD. The study represents a significant breakthrough in this field, proving that there is a connection between distinct voice features and health conditions, which can significantly improve continuous monitoring and reduce remote healthcare costs.
Boston Scientific has acquired the gynecology and urology portfolio of Distal Access, LLC, a Salt Lake City based company that designs minimally invasive medical devices. The portfolio includes the Resectr™ Tissue Resection Device, a single-use solution designed to effectively remove uterine polyps.